Skip to main content
. 2018 Feb 8;4(5):717–721. doi: 10.1001/jamaoncol.2017.5332

Figure 3. Kaplan-Meier Curves for Overall Survival of Partial Response Patients According to Circulating Tumor DNA (ctDNA) Profile.

Figure 3.

A total of 16 deaths occurred in patients with Response Evaluation Criteria in Solid Tumors (RECIST) progressive disease at week 12. All deaths were related to disease progression at a median follow-up of 110 weeks (range: 13-167 weeks). Landmarked data were used to calculate hazard ratio (HR) of overall survival for 27 patients at week 6 and 29 patients at week 12. Results include an unfavorable ctDNA profile at week 6 (HR, 3.9; 95% CI, 2.1-14.0; P = .02) and week 12 (HR, 3.3; 95% CI, 1.0-10.5; P = .03). The 1-year overall survival was 100% for patients with partial response, 81.8% for those with a favorable ctDNA profile, and 38.9% for those with an unfavorable ctDNA profile.